The first effects of the arrival of the European Medicines Agency EMA are already being felt.
The EMA effect is also good news for scientific research. Director Bart Klijsen of IXA VU-VUmc says, “In order to bring research to society, cooperation and participation with companies is indispensable. This requires a mature ecosystem. That is why the arrival of EMA is positive for the Netherlands and for the region. Although not all contacts are directly related to EMA, there is a lot more interest from the medical industry in Amsterdam.”
Read the full Parool article of Herman Stil, Artikel-Parool-Als-EMA-over-de-dam-is…..pdf
MedTech startup Sirius Medical has received CE Mark approval for Sirius Pintuition, a non-radioactive device to localize breast tumors. In 2016 Bram Schermers, then a scientist at NKI, pitched an early concept at the annual Amsterdam Science & Innovation Awards and won first prize! His pitch also caught the attention of seasoned entrepreneur Hubert Martens, […]News
CimCure, a spin-off of Amsterdam UMC and focusing on cancer immunotherapies for solid tumors, signed a strategic partnership agreement for in-licensing CimCure’s iBoost technology with Intravacc, a worldwide leading translational research and development vaccine organization with an extensive track record in developing viral and bacterial vaccines. The iBoost (immune boost) technology was developed at Amsterdam […]News
An annual survey held by the program directors of the Joint Master Entrepreneurship (UvA/ VU), Bram Kuijken and Enno Masurel, has found that 17.8% of alumni have founded their own company and 11.0% are currently working freelance. Additionally, the study found that 41.9% of alumni is employed by a startup (19.7%) or a scale-up (22.2%). […]News